Top Markets
Coin of the day
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rang in aandelen #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aandeelprijs
$2.70
Laatst gesynchroniseerd: 2023-05-17
Marktkapitalisatie
$4.13M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Categorie

EPS voor Graybug Vision, Inc. (GRAY)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Graybug Vision, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Graybug Vision, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten